Psychedelics activate the 5-HT2A receptor, upregulate brain-derived neurotrophic factor, and enhance synaptic plasticity, leading to therapeutic potential for stress and psychiatric disorders. Credit ...
This article was originally published on Psychedelic Spotlight and appears here with permission. New study suggests that a non-hallucinogenic LSD analog may hold therapeutic potential for mood ...
Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.
A new study provides a detailed look at how the psychedelic compound psilocin acts on specific neurons within the brain. The ...
2A Biosciences Inc. has divulged compounds acting as 5-HT2A and 5-HT2C receptor agonists reported to be useful for the treatment of atopic dermatitis, conjunctivitis, Crohn’s disease, type 2 diabetes, ...
STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...
Image of a cortical neuron (white) expressing serotonin 2A (5-HT2A) receptors (multicolor). New work shows that engaging 5-HT2A receptors inside cells, but not on the cell surface, encourages cell ...
The human brain can change — but usually only slowly and with great effort, such as when learning a new sport or foreign language or recovering from a stroke. Learning new skills correlates with ...
SEATTLE, WA and IRVINE, CA / ACCESSWIRE / October 5, 2023 / Küleon LLC, a private biotechnology company that has built the industry's largest library of serotonergic drugs exhibiting G protein-biased ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback